Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ADC Therapeutics stock | $28.29

Learn how to easily invest in ADC Therapeutics stock.

ADC Therapeutics SA is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. ADC Therapeutics employs 208 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ADC Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ADCT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ADC Therapeutics stock price (NYSE: ADCT)

Use our graph to track the performance of ADCT stocks over time.

ADC Therapeutics shares at a glance

Information last updated 2021-09-19.
Latest market close$28.29
52-week range$20.01 - $46.20
50-day moving average $26.67
200-day moving average $24.39
Wall St. target price$43.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.67

Buy ADC Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ADC Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADC Therapeutics price performance over time

Historical closes compared with the close of $28.29 from 2021-09-24

1 week (2021-09-17) -1.98%
1 month (2021-08-25) 9.40%
3 months (2021-06-25) 12.80%
6 months (2021-03-25) 7.12%
1 year (2020-09-25) -15.75%
2 years (2019-09-21) N/A
3 years (2018-09-21) N/A
5 years (2016-09-21) N/A

ADC Therapeutics financials

Revenue TTM $3.8 million
Gross profit TTM $-141,816,000
Return on assets TTM -40.47%
Return on equity TTM -91.02%
Profit margin 0%
Book value $3.18
Market capitalisation $2.3 billion

TTM: trailing 12 months

Shorting ADC Therapeutics shares

There are currently 6.0 million ADC Therapeutics shares held short by investors – that's known as ADC Therapeutics's "short interest". This figure is 11.2% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting ADC Therapeutics shares can be evaluated.

ADC Therapeutics's "short interest ratio" (SIR)

ADC Therapeutics's "short interest ratio" (SIR) is the quantity of ADC Therapeutics shares currently shorted divided by the average quantity of ADC Therapeutics shares traded daily (recently around 301907.22528851). ADC Therapeutics's SIR currently stands at 19.93. In other words for every 100,000 ADC Therapeutics shares traded daily on the market, roughly 19930 shares are currently held short.

However ADC Therapeutics's short interest can also be evaluated against the total number of ADC Therapeutics shares, or, against the total number of tradable ADC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADC Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ADC Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.2042% of the tradable shares (for every 100,000 tradable ADC Therapeutics shares, roughly 204 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ADC Therapeutics.

Find out more about how you can short ADC Therapeutics stock.

ADC Therapeutics share dividends

We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.

ADC Therapeutics overview

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B. V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. .

Stocks similar to ADC Therapeutics

Frequently asked questions

What percentage of ADC Therapeutics is owned by insiders or institutions?
Currently 51.352% of ADC Therapeutics shares are held by insiders and 44.423% by institutions.
How many people work for ADC Therapeutics?
Latest data suggests 208 work at ADC Therapeutics.
When does the fiscal year end for ADC Therapeutics?
ADC Therapeutics's fiscal year ends in September.
Where is ADC Therapeutics based?
ADC Therapeutics's address is: Biopole, Epalinges, Switzerland, 1066
What is ADC Therapeutics's ISIN number?
ADC Therapeutics's international securities identification number is: CH0499880968

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site